Allina Health is a not-for-profit health care system based in Minneapolis, Minnesota, United States. Allina Health owns or operates 12 hospitals and more than 90 clinics throughout Minnesota and western Wisconsin. In addition Allina Medical Transportation covers 8 regions and over 80 communities providing medical dispatch, 911 pre-arrival instructions, and emergency and non-emergency ambulance response.
Local failure and leptomeningeal disease (LMD) are both poor outcomes that can occur after resection and post-operative radiosurgery for newly diagnosed brain metastases (BM). There is increasing utilization of collagen-embedded Cesium-131 brachytherapy (GammaTile®) as a method of providing immediate adjuvant radiation therapy. Post-operative LMD rates following GammaTile implantation for newly diagnosed BMs has yet to be reported. The objective was to evaluate the incidence of LMD rates, local control (LC), and survival following resection and GammaTile for newly diagnosed BMs. An ongoing, multicenter, prospective, observational Phase IV non-interventional registry (NCT0442738) was queried to analyze rates of LMD following surgical resection of newly diagnosed BMs. Following resection and GammaTile implantation, we evaluated LMD rates, LC, and overall survival (OS). The Kaplan-Meier method was used to analyze time-to-event outcomes. Fifty-one patients with 55 BMs were analyzed. The median follow-up was 12.4 months. The majority of BMs were in the supratentorial brain (87.3
Background/Objectives: Non-muscle invasive bladder cancer (NMIBC) management is increasingly complex due to conflicting guideline-based risk classifications, ongoing Bacillus Calmette-Guérin (BCG) shortages, and emerging alternative therapies. Computational Histology Artificial Intelligence (CHAI) tests are clinically available, providing insights from tumor specimens including predicting BCG responsiveness and individualized recurrence and progression risks, which may support precision medicine. This technology features biomarkers purpose-built for clinically unmet needs and has practical advantages including a fast turnaround time and no need for consumption of tissue or other specimens. We assessed the impact of such tests on physicians' decision-making in routine, real-world NMIBC management. Methods: Physicians at six centers ordered CHAI tests (Vesta Bladder) at their discretion during routine NMIBC care. Tumor specimens were processed by a CLIA/CAP-accredited laboratory (Valar Labs, Houston, TX, USA) where H&E-stained slides were analyzed with the CHAI assay to extract histomorphic features of the tumor and microenvironment, which were algorithmically assessed to generate biomarker test results. For each case from 24 June 2024 to 18 July 2025, ordering physicians were surveyed to assess pre- and post-test management plans and post-test result usefulness. Results: Among 105 high-grade NMIBC cases with complete survey results available, primary management changed in 67% (70/105). Changes included modality shifts (n = 7; three to radical cystectomy with high prognostic risk scores; four avoiding cystectomy with low scores) and intravesical agent change (n = 63). Surveillance was intensified in 7%, predominantly among those with ≥90th percentile risk scores. The therapeutic agent changed in 80% (40/50) of predictive biomarker-present (indicative of poor response to BCG) tumors vs. 48% (23/48) of biomarker-absent tumors. Conclusions: In two thirds of cases, CHAI biomarker results influenced clinical decision-making during routine care. BCG predictive biomarker results frequently guided intravesical agent selection. These results have implications for optimizing clinical outcomes, especially in the setting of ongoing BCG shortages. Prognostic risk stratification results guided treatment escalation vs. de-escalation, including surveillance intensification and surgical vs. bladder-sparing decisions. CHAI biomarkers are currently utilized in routine clinical care and informing precision NMIBC management.
Empirical evidence on COVID-19 vaccination and lactation-related outcomes remains limited. We used electronic health record data from 4 US healthcare systems to assess the association between COVID-19 vaccination and milk feeding outcomes. We included pregnant persons with a live birth between December 2020 and September 2022 with infant linkage. We assessed 2 COVID-19 vaccination exposure windows-during pregnancy (≥20 weeks gestation vs no vaccination during pregnancy) or postpartum (<7 months after delivery vs none). We estimated adjusted prevalence ratios (aPR) for COVID-19 vaccination during pregnancy and human milk feeding non-initiation and discontinuation, and we estimated adjusted hazard ratios (aHR) for postpartum COVID-19 vaccination and human milk feeding discontinuation. In the study population used to assess pregnancy exposure (N = 10 757), 4.2% of birthing parents did not initiate human milk feeding. Non-initiation did not differ by vaccination during pregnancy (aPR = 0.99; 95% CI, 0.98-1.01). Antenatal vaccination was not associated with human milk feeding discontinuation at 2 and 6 months after delivery. In the study population used to assess postpartum exposure (N = 17 161), human milk feeding discontinuation did not differ by postpartum vaccination (aHR = 1.03; 95% CI, 0.95-1.11). COVID-19 vaccination in pregnancy and postpartum were not associated with human milk feeding discontinuation.
Background High-grade astrocytoma with piloid features (HGAP) is a recently defined tumor type that is not well understood. Prognostic factors of clinical outcomes are not well established.Methods Methylation profiling was performed on tumor samples, many at the National Cancer Institute (NCI) Laboratory of Pathology, and others from publicly available sources. Methylation classifier scores of >= 0.90 to the HGAP class on the NCI-Bethesda classifier version 3 were included. Clinical features were collected from the medical record. Survival analyses were performed using the Kaplan-Meier and Cox-proportional hazards methods.Results The cohort comprised 421 patients. There were high rates of ATRX alteration (62%), CDKN2A/B homozygous loss (78%) and MGMT promoter methylation (53%). MAPK alterations were identified in 74% of evaluable samples. The median age was 46 years, and posterior fossa location was predominant (52%). The median overall survival was 88 months. Older age (P = .01) and the presence of an ATRX alteration (P = .04) were found to be negative prognostic factors. The presence of cystic features on magnetic resonance imaging (MRI) was found to be favorably prognostic (P = .01). Factors that were not significantly associated with prognosis included histologic high-grade features, CDKN2A/B homozygous deletion, MGMT promoter methylation, extent of resection, and presence of NF1 syndrome.Conclusions This large cohort establishes relative frequencies of several important markers. Additionally, older age, the presence of an ATRX alteration, and cystic features on MRI were found to be prognostic. Our work may aid in optimizing treatment regimens for patients with this tumor type. There have been few large studies studying patients with high-grade astrocytoma with piloid features (HGAP). The goal was to study the tissue, imaging and survival outcomes in a large cohort (421 unique patients). On average, patients lived for about 7 years in this cohort. Factors that affected survival included older age and an alteration in a particular gene "ATRX," and presence of cystic (fluid-filled sacs) parts found in the tumor. We hope this better characterizes HGAP and helps aid physicians in identifying the best treatment options.